Japan's Takeda Pharma says full-year profit up five-fold

Credit: REUTERS/KIM KYUNG-HOON

Takeda Pharmaceutical Co said on Tuesday that full-year operating profit jumped five-fold from the previous year, driven by sales of its Entyvio colitis treatment and other mainstay drugs.

TOKYO, May 11 (Reuters) - Takeda Pharmaceutical Co 4502.T said on Tuesday that full-year operating profit jumped five-fold from the previous year, driven by sales of its Entyvio colitis treatment and other mainstay drugs.

Operating profit for Japan's largest drugmaker in the year that ended in March came in at 509 billion yen ($4.68 billion).

That compares with its own earlier estimate of 434 billion yen and a consensus estimate of 567 billion yen from a Refinitiv poll of 14 analysts.

Takeda is importing Moderna Inc's MRNA.O COVID-19 vaccine into Japan and on Monday said that interim results of clinical trials have been positive.

($1 = 108.8600 yen)

(Reporting by Rocky Swift; Editing by Kim Coghill)

((rocky.swift@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More